Qingdao Baheal Medical 百洋医药
14 significant filings since 30 May 2026: 2 on share pledge, 1 on litigation and 7 on guarantee or financial assistance, and 3 other kinds. The latest, on 11 Sep 2026: 关于为子公司提供担保的进展公告.
自 30 May 2026 起有 14 份重大公告：share pledge 2 份、litigation 1 份、guarantee or financial assistance 7 份，另有 3 类。最新一份（11 Sep 2026）：关于为子公司提供担保的进展公告。
Price History 价格走势
5 sessions 个交易日, 18 Sep to 24 Sep 2026 · Live one-minute prices · High 最高 ¥26.71 · Low 最低 ¥23.21 · −3.41% on the previous close of ¥26.12The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 29 Aug 2023 | 国金证券 | 赵海春 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 华鑫证券 | 胡博新,吴景欢 | Buy 买入 | 10 Sep 2026 | 1 | — |
| 西南证券 | 杜向阳 | Unrated | 8 May 2026 | 1 | — |
| 开源证券 | 余汝意,巢舒然 | Buy 买入 | 30 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。